drugset / Trial / NCT00004873

Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer

NCT00004873 ↗

Phase 2 Completed Swiss Cancer Institute
RandomizedTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating advanced stomach cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of different regimens of combination chemotherapy in treating patients who have advanced stomach cancer.

Timeline

Start
1999-08
Primary completion
2003-07
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 60 mg/m2 Intravenous
Subject Cisplatin Other / unclassified 75 mg/m2 Intravenous
Subject Docetaxel Small molecule 75 mg/m2 Intravenous
Subject Docetaxel Small molecule 85 mg/m2 Intravenous
Subject Epirubicin Small molecule 50 mg/m2 Intravenous
Subject fluorouracil Small molecule 200 mg/m2 Intravenous
Subject fluorouracil Small molecule 300 mg/m2 Intravenous

Indications